International Clinical Trial: A prospective, single-arm, multicenter study of Camrelizumab combined with chemotherapy and Ivarmacitinib as first-line treatment for advanced NSCLC

Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119574) titled 'A prospective, single-arm, multicenter study of Camrelizumab combined with chemotherapy and Ivarmacitinib as first-line treatment for advanced NSCLC' on Feb. 28.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: West China Hospital of Sichuan University

Condition: Advanced non-small cell lung cancer

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-04-01

Target Sample Size: Experimental Group:60;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=311855

Published by HT Digital Content Services with per...